Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Huang Ying 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol Legend Biotech Corp [LEGN] (Last) (First) (Middle) C/O LEGEND BIOTECH CORP, 2101 COTTONTAIL LANE 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SOMERSET, NJ 08873 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares(1) 257,374(2) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(3)	07/21/2029	Ordinary Shares	81,788	$1.5	D
Share Option (right to buy)	(3)	06/29/2032	Ordinary Shares	3,636	$27.5	D
Share Option (right to buy)	(4)	04/02/2033	Ordinary Shares	4,248	$23.53	D
Share Option (right to buy)	(3)	07/21/2029	Ordinary Shares	35,728	$1.5	D
Share Option (right to buy)	(3)	07/21/2029	Ordinary Shares	121,746	$1.5	D
Share Option (right to buy)	(3)	03/25/2031	Ordinary Shares	92,134	$14.12	D
Share Option (right to buy)	(3)	06/29/2032	Ordinary Shares	185,340	$27.5	D
Share Option (right to buy)	(5)	04/02/2033	Ordinary Shares	55,752	$23.53	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Huang Ying C/O LEGEND BIOTECH CORP 2101 COTTONTAIL LANE SOMERSET, NJ 08873	X		Chief Executive Officer

Signatures

/s/ James Pepin, Attorney-in-Fact		03/18/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
(2)	Includes 43,010 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 28,119 shares underlying the RSU will vest on March 20, 2026 and the remaining 14,891 shares will vest on June 20, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
(3)	All of the shares subject to the option are immediately exercisable.
(4)	All of the shares subject to the option shall vest on April 3, 2026.
(5)	40,000 of the shares subject to the option are immediately exercisable and the remainder shall vest on April 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Remarks: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.